First clinical trials of anticovid vaccine begin in Argentina | News

The National Administration of Medicines, Food and Medical Technology (Anmat) of Argentina announced this Wednesday the start of the first phase of clinical trials of the vaccine candidate against Covid-19, Arvac Cecilia Grierson.

READ ALSO:

Venezuelan deputies request investigation into Operation Puma

According to the entity, the development of the anticovid drug in the South American nation responds to the four projects that will be promoted by the Argentine government against the increase in the number of infections by the SARS-CoV-2 virus, which causes the pandemic.

Likewise, the Nation’s Minister of Health, Carla Vizzotti, specified that the achievement obtained by the scientific staff, involved in clinical trials, represents an important milestone for research in the country.



“In the Coronavirus Unit, we selected the initiative led by the researcher Juliana Cassataro, who was the germ of this vaccine based on recombinant proteins, a technology similar to that used in the Hepatitis B or HPV vaccine,” indicated the National Promotion Agency. Research, Technological Development and Innovation (R+D+i Agency).

In this sense, the R+D+i Agency stressed that the new vaccine candidate against Covid-19 generated capacities and is a solution to the demands of Argentine society.

For her part, the head of the multidisciplinary team in charge of the project, Juliana Cassataro, reported that the clinical trial will evaluate the safety of the anticovid immunizer in people, and then examine the response in citizens previously vaccinated against the disease.